{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:57:57Z","timestamp":1772510277338,"version":"3.50.1"},"reference-count":125,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":10363,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1983,9,10]]},"abstract":"<jats:p>Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. However, its antineoplastic spectrum more closely resembles that of vincristine. Clinical studies indicate activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus and head and neck, Hodgkin's disease and non\u2010Hodgkin's lymphomas. Pharmacokinetic studies indicate that vindesine exhibits a triphasic elimination pattern with a terminal half\u2010life of 24.2 hours. Elimination is primarily through hepatic metabolism. The major side effects associated with vindesine therapy are myelosuppression and neurotoxicity. Other side effects include alopecia, nausea and vomiting and local tissue irritation associated with extravasation. Vindesine will be a positive addition to the antineoplastic armamentarium. The full extent of its activity remains to be established.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1983.tb03269.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T19:51:48Z","timestamp":1450295508000},"page":"259-272","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid"],"prefix":"10.1002","volume":"3","author":[{"given":"Robert J.","family":"Cersosimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bromer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jere T. W.","family":"Licciardello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waun Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257185"},{"key":"e_1_2_1_3_2","first-page":"28","article-title":"Vindesine sulfate","volume":"14","author":"Dana WJ","year":"1980","journal-title":"Drug Intell Clin Pharm"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","unstructured":"BradeWP.Critical review of pharmacology toxicology pharmacokinetics of vincristine vindesine vinblastine. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:95\u2013123.","DOI":"10.1159\/000428623"},{"key":"e_1_2_1_5_2","first-page":"437","article-title":"Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines","volume":"67","author":"Hill BJ","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950100202"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257188"},{"key":"e_1_2_1_8_2","first-page":"2603","article-title":"Pharmacokinetics of vindesine and vincristine in humans","volume":"37","author":"Owellen RJ","year":"1977","journal-title":"Cancer Res"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(77)80010-8"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950100107"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257194"},{"key":"e_1_2_1_12_2","first-page":"1331","volume":"2","author":"Krivit W","year":"1978","journal-title":"Vindesine - a phase II study by the children's cancer study group"},{"key":"e_1_2_1_13_2","first-page":"1","article-title":"Phase II clinical trials with vindesine in patients with hematological malignancies","volume":"1","author":"Math\u00e9 G","year":"1981","journal-title":"Anticancer Res"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810615)47:12<2789::AID-CNCR2820471205>3.0.CO;2-X"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257189"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","unstructured":"HulhovenR MichauxJL CornuGet al.Vindesine and prednisone in the treatment of relapsed lymphomalignancies blastic crisis of chronic myelocytic leukemia and acute myelomonocytic leukemia. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:143\u201350.","DOI":"10.1159\/000428626"},{"key":"e_1_2_1_17_2","first-page":"4301","article-title":"Childhood leukemia as a model for cancer research. The Richard and Hinda Rosenthal Foundation Award Lecture","volume":"39","author":"Simone JV","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_1_18_2","first-page":"1567","volume":"2","author":"Anderson J","year":"1980","journal-title":"Cross-resistance of vincristine and vindesine in reinduction therapy for acute leukemia in relapse"},{"key":"e_1_2_1_19_2","first-page":"1015","article-title":"Comparison of therapeutic response of patients with childhood lymphoblastic leukemia in relapse to vindesine vs vincristine in combination with prednisone and 1\u2010asparaginase: a phase III trial","volume":"65","author":"Anderson J","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257193"},{"key":"e_1_2_1_21_2","first-page":"217","article-title":"A study of the cross\u2010resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report of the children's cancer study group","volume":"2","author":"Krivit W","year":"1980","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950080306"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","unstructured":"EnglehardtR BrossK WeberMet al.Phase II trial with vindesine in patients with hematologic malignancies mainly blast crisis of chronic myelogenous leukemia. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:134\u201342.","DOI":"10.1159\/000428625"},{"key":"e_1_2_1_24_2","first-page":"155","volume":"2","author":"Mandelli F","year":"1981","journal-title":"Vindesine in the treatment of refractory hematologic malignancies: a phase II study (abstract)"},{"key":"e_1_2_1_25_2","first-page":"135","article-title":"Vindesine and ICRF\u2010159 combination chemotherapy (abstract)","volume":"21","author":"Stevens EE","year":"1980","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_26_2","first-page":"699","article-title":"Therapie der blastenkrise der chronischen myeloischen leukemie \u2010 ergibnisse einer phasen II studie mit vindesin","volume":"108","author":"Hellriegel KP","year":"1981","journal-title":"Folia Haematol (Leipz)"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V38.6.671.671"},{"key":"e_1_2_1_28_2","first-page":"1385","article-title":"Use of vindesine in the terminal phase of chronic myelocytic leukemia","volume":"63","author":"Gomez GA","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197902)43:2<426::AID-CNCR2820430204>3.0.CO;2-H"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197804132981503"},{"key":"e_1_2_1_31_2","first-page":"179","volume":"4","author":"Raich P","year":"1981","journal-title":"Therapeutic spectrum of vindesine in breast cancer, lymphoma, and acute leukemia (abstract)"},{"key":"e_1_2_1_32_2","first-page":"338","article-title":"Etude de la vindesine en perfusion de 5 jours dans le traitement des leucemies et lymphomes","volume":"68","author":"Maraninchi D","year":"1981","journal-title":"Bull Cancer (Paris)"},{"key":"e_1_2_1_33_2","first-page":"793","article-title":"Phase II trial of vindesine in patients with malignant lymphoma","volume":"63","author":"Sklaroff RB","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80013-2"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","unstructured":"JonesSE MillerTP RobertoneAet al.Vincristine or vindesine plus BCNU Adriamycin and prednisone for refractory lymphoma. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:151\u20135.","DOI":"10.1159\/000428627"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","unstructured":"TenHuininkBokkel WW LindenVan DerHamersma B CletonFJ.Vindesine in breast cancer and lymphomas. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:172\u20135.","DOI":"10.1159\/000428630"},{"key":"e_1_2_1_37_2","first-page":"30","article-title":"A phase II study of vindesine in patients with advanced breast cancer, melanoma, and lymphomas (abstract)","volume":"23","author":"DiBella N","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_38_2","first-page":"1565","volume":"2","author":"Retsas S","year":"1980","journal-title":"Evaluation of vindesine in the treatment of recurrent malignant lymphomas"},{"key":"e_1_2_1_39_2","first-page":"141","volume":"12","author":"Boston B","year":"1981","journal-title":"Randomized comparison of vindesine (DVA) vs DVA and cisplatin (DDP) in non-small cell lung cancer (abstract)"},{"key":"e_1_2_1_40_2","first-page":"260","volume":"12","author":"Aisner J","year":"1981","journal-title":"Vindesine (DVS) and platinum (DDP) for previously treated lung cancer (abstract)"},{"key":"e_1_2_1_41_2","first-page":"1330","volume":"2","author":"Young C","year":"1978","journal-title":"Early phase II evaluation of vindesine in patients with advanced disease"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80012-0"},{"key":"e_1_2_1_43_2","first-page":"877","article-title":"Broad phase II study of vindesine","volume":"65","author":"Valdivieso M","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_44_2","first-page":"1569","volume":"2","author":"Mattson K","year":"1980","journal-title":"Vindesine in the treatment of bronchogenic carcinoma: preliminary results of two clinical trials"},{"key":"e_1_2_1_45_2","first-page":"41","article-title":"Vindesine in bronchogenic carcinoma: a phase II trial","volume":"5","author":"Vogelzang N","year":"1982","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_46_2","first-page":"1409","article-title":"Vindesine (VDS) monochemotherapy for non\u2010small cell lung cancer: a report of 45 cases","volume":"66","author":"Luedke S","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_47_2","first-page":"305","article-title":"Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung","volume":"66","author":"Osterlind K","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80009-0"},{"key":"e_1_2_1_49_2","first-page":"1709","article-title":"Vindesine: an effective agent in the treatment of non\u2010small cell lung cancer","volume":"66","author":"Furnas B","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_50_2","first-page":"536","article-title":"Phase II study of vindesine (DVA) infusion in advanced cancer (abstract)","volume":"22","author":"Popkin J","year":"1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_51_2","doi-asserted-by":"crossref","unstructured":"DirksH DringsP MankeHet al.Continuous vindesine infusion therapy in cases of advanced non\u2010small cell bronchogenic carcinoma. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:344\u20137.","DOI":"10.1159\/000428658"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","unstructured":"HongW PennacchioJ PugatchRet al.Vindesine vs vindesine with cis\u2010platinum in metastatic non\u2010small cell lung cancer. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:398\u2013404.","DOI":"10.1159\/000428666"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197703)39:3<1026::AID-CNCR2820390305>3.0.CO;2-P"},{"key":"e_1_2_1_54_2","first-page":"125","article-title":"Clinical studies of vinblastine","volume":"12","author":"Frei E","year":"1961","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_55_2","first-page":"169","article-title":"Vinblastine in neoplastic disease","volume":"23","author":"Wright T","year":"1963","journal-title":"Cancer Res"},{"key":"e_1_2_1_56_2","first-page":"1258","article-title":"Vincristine treatment of advanced cancer: a cooperative study of 392 cases","volume":"33","author":"Holland J","year":"1973","journal-title":"Cancer Res"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(78)90252-9"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-1378-6_14"},{"key":"e_1_2_1_59_2","first-page":"1341","article-title":"Phase II clinical trials with high dose cisplatin with mannitol induced diuresis in advanced bronchogenic cancer","volume":"64","author":"DeJager R","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-4-414"},{"key":"e_1_2_1_61_2","first-page":"141","volume":"12","author":"Holsti L","year":"1981","journal-title":"Cisplatin in combination with vindesine vs VP-16 in the treatment of epidermoid carcinoma of the lung (abstract)"},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","unstructured":"BoloqkeiP KleinfelderH KrasaZet al.Experience with the combination of cis\u2010platinum and vindesine in the treatment of squamous cell carcinomas adenocarcinomas and large cell bronchogenic carcinomas. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:392\u20137.","DOI":"10.1159\/000428665"},{"key":"e_1_2_1_63_2","first-page":"247","article-title":"Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non\u2010small cell lung cancer","volume":"66","author":"Kelsen D","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_64_2","first-page":"553","article-title":"Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5\u2010FU, vindesine, and mitomycin (FEMi): a southwest oncology group study","volume":"66","author":"Miller T","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_65_2","first-page":"49","article-title":"A phase II trial of vindesine in patients with refractory small cell carcinoma of the lung","volume":"5","author":"Fuks J","year":"1982","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_66_2","first-page":"245","article-title":"Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma","volume":"65","author":"Osterlind K","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_67_2","first-page":"129","article-title":"Phase II trial of vindesine in patients with small cell lung carcinoma","volume":"65","author":"Natale R","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_68_2","first-page":"143","article-title":"Vindesine sulfate (VND) a phase II trial in small cell bronchogenic carcinoma (SCCL) (abstract)","volume":"23","author":"Witte R","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_69_2","first-page":"500","article-title":"Phase II study of vindesine (V) in refractory small cell carcinoma of the lung (SCC) (abstract)","volume":"22","author":"Petruska P","year":"1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_70_2","first-page":"1738","volume-title":"Cancer medicine","author":"Selawry O","year":"1982"},{"key":"e_1_2_1_71_2","doi-asserted-by":"crossref","unstructured":"HavermannK GroppC GasselWet al.Treatment of small cell lung cancer with polychemotherapy consisting of VP\u201016\u2010213 iphosfamide and vindesine. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:337\u201341.","DOI":"10.1159\/000428656"},{"key":"e_1_2_1_72_2","doi-asserted-by":"crossref","unstructured":"FocanC HungS BaysRet al.Methotrexate cyclophosphamide and vindesine vs methotrexate cyclophosphamide and vinblastine in advanced lung cancer. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:371\u201385.","DOI":"10.1159\/000428663"},{"key":"e_1_2_1_73_2","doi-asserted-by":"crossref","unstructured":"NiederleN KrlschkeC SchmidtCet al.Vindesine plus cisplatin chemotherapy in recurrent and primarily resistant small cell bronchogenic carcinoma. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:314\u20139.","DOI":"10.1159\/000428653"},{"key":"e_1_2_1_74_2","first-page":"179","article-title":"Phase II trial of vindesine in patients with malignant melanoma","volume":"64","author":"Camacho FJ","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_75_2","first-page":"355","article-title":"Phase II study of vindesine in metastatic malignant melanoma, (letter)","volume":"65","author":"Arseneau JC","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_76_2","first-page":"182","article-title":"Vindesine in patients with metastatic malignant melanoma","volume":"23","author":"Quagliana J","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_77_2","first-page":"134","article-title":"Continuous five\u2010day infusion of vindesine in the treatment of metastatic malignant melanoma (abstract)","volume":"23","author":"Yap B","year":"1982","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80014-4"},{"key":"e_1_2_1_79_2","first-page":"1427","article-title":"Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors","volume":"62","author":"Smith IE","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_80_2","doi-asserted-by":"crossref","unstructured":"FiorentinoM FerrazziE MonfardiniSet al.Vindesine (VDS) in Padua and Milan. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:227\u20138.","DOI":"10.1159\/000428642"},{"key":"e_1_2_1_81_2","first-page":"165","article-title":"DTIC (NSC\u201045388) in malignant melanoma: a prospective","volume":"60","author":"Comis RL","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_82_2","first-page":"169","article-title":"Combination chemotherapy with vindesine and DTIC in advanced malignant melanoma (abstract)","volume":"23","author":"Retsas S","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_83_2","first-page":"185","article-title":"Cisplatin and vindesine combination chemotherapy in advanced malignant melanoma (abstract)","volume":"23","author":"Dodion P","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_84_2","first-page":"178","article-title":"DTIC and continuous five\u2010day infusion of vindesine \u00b1 MER for metastatic malignant melanoma (abstract)","volume":"23","author":"Yap BS","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_85_2","first-page":"1399","article-title":"Phase II trial of vindesine in patients with germ cell tumors","volume":"63","author":"Reynolds TF","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_86_2","doi-asserted-by":"crossref","unstructured":"SchmollHJ.Vindesine in melanoma testicular cancer head and neck cancer myeloma and other solid tumors except breast and lung cancer: a critical review. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:289\u2013312.","DOI":"10.1159\/000428652"},{"key":"e_1_2_1_87_2","first-page":"1141","article-title":"Phase II trial of vindesine in advanced head and neck cancer","volume":"64","author":"Cheng E","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_88_2","first-page":"199","article-title":"Phase II trial of vindesine in squamous cancer of the head and neck (abstract)","volume":"23","author":"Kaplan BH","year":"1982","journal-title":"Proc Am Soc Cin Oncol"},{"key":"e_1_2_1_89_2","first-page":"180","volume":"12","author":"Muniz F","year":"1981","journal-title":"Phase II study of vindesine in advanced squamous cell esophageal and head and neck carcinomas (abstract)"},{"key":"e_1_2_1_90_2","article-title":"Continuous vindesine infusion in advanced head and neck cancer","author":"Popkin JD","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_91_2","first-page":"301","volume-title":"Cancer principles and practice of oncology","author":"Million RR","year":"1982"},{"key":"e_1_2_1_92_2","first-page":"583","article-title":"Phase II evaluation of vindesine for patients with advanced colorectal carcinoma","volume":"66","author":"Saiers JH","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_93_2","first-page":"2097","article-title":"Phase II evaluation of vindesine in patients with advanced colorectal carcinoma","volume":"63","author":"Carroll DS","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800801)46:3<463::AID-CNCR2820460307>3.0.CO;2-P"},{"key":"e_1_2_1_95_2","first-page":"146","article-title":"Phase II trial of vindesine (VND) in advanced metastatic cancer (abstract)","volume":"20","author":"Rossof AH","year":"1979","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_96_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0305-7372(74)80007-1","article-title":"Integration of chemotherapy into combined modality therapy of solid tumors. II Large bowel carcinoma","volume":"1","author":"Carter SK","year":"1974","journal-title":"Cancer Treat Rev"},{"key":"e_1_2_1_97_2","first-page":"643","volume-title":"Cancer principles and practice of oncology","author":"Sugarbaker PH","year":"1982"},{"key":"e_1_2_1_98_2","doi-asserted-by":"crossref","unstructured":"BodeyGP ValdiviesoM BedikianAYet al.Vindesine in the therapy of solid tumers. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:84\u201391.","DOI":"10.1159\/000428621"},{"key":"e_1_2_1_99_2","first-page":"2019","article-title":"Vindesine in the treatment of esophageal carcinoma: a phase II study","volume":"63","author":"Kelsen DP","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_100_2","first-page":"643","volume-title":"Cancer principles and practice of oncology","author":"Rosenberg JC","year":"1982"},{"key":"e_1_2_1_101_2","first-page":"493","article-title":"Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin","volume":"57","author":"Ravry M","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_102_2","first-page":"781","article-title":"Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma","volume":"65","author":"Kelsen DP","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_103_2","first-page":"693","article-title":"Phase II evaluation of vindesine in patients with advanced breast cancer","volume":"64","author":"Currie VE","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_104_2","first-page":"659","article-title":"Phase II study of vindesine in patients with metastatic breast cancer","volume":"65","author":"Cobleigh MA","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_105_2","first-page":"371","article-title":"Vindesine a phase II trial in advanced breast cancer patients","volume":"4","author":"Robins HI","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_106_2","first-page":"445","article-title":"Phase II trial of vindesine (DVA) in advanced breast cancer patients (abstract)","volume":"22","author":"Skelley M","year":"1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_107_2","first-page":"172","article-title":"Phase II trial of weekly vindesine in early metastatic breast cancer (abstract)","volume":"21","author":"Dosik M","year":"1980","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_108_2","first-page":"1729","article-title":"Phase II study of vindesine in patients with advanced breast cancer","volume":"66","author":"Walker BK","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_109_2","first-page":"914","volume-title":"Cancer principles and practice of oncology","author":"Hellman S","year":"1982"},{"key":"e_1_2_1_110_2","first-page":"279","article-title":"Vinblastine given as a continuous 5\u2010day infusion in the treatment of refractory advanced breast cancer","volume":"64","author":"Yap HY","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_111_2","first-page":"775","article-title":"Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5\u2010day infusion","volume":"65","author":"Yap HY","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_112_2","first-page":"82","article-title":"Comparability in therapeutic index with continuous 5\u2010day infusion and 5\u2010day bolus vindesine in the treatment of refractory breast cancer (abstract)","volume":"23","author":"Fleishman GB","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80011-9"},{"key":"e_1_2_1_114_2","doi-asserted-by":"crossref","unstructured":"NagelGA.Therapeutic results with vinca alkaloids in metastatic breast cancer with special reference to vindesine \u2010 a critical review. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:214\u201320.","DOI":"10.1159\/000428640"},{"key":"e_1_2_1_115_2","doi-asserted-by":"crossref","unstructured":"QueiberW VossI MabnerBet al.Treatment of advanced breast cancer with vindesine carmustine and tamoxifen in patients no longer responsive to Adriamycin 5\u2010fluorouracil methotrexate and cyclophosphamide combinations. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:188\u201394.","DOI":"10.1159\/000428635"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80007-7"},{"key":"e_1_2_1_117_2","doi-asserted-by":"crossref","unstructured":"HouwenB VandobbenburghOA MarrinkJet al.Vindesine\u2010prednisone combination in advanced multiple myeloma resistant to alkylating agents. In: Proceedings of the international vinca alkaloid symposium \u2010 vindesine. Frankfurt 1981:239\u201349.","DOI":"10.1159\/000428644"},{"key":"e_1_2_1_118_2","first-page":"1727","article-title":"Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma","volume":"61","author":"Wong PP","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_119_2","first-page":"173","article-title":"Initial clinical studies of vindesine","volume":"65","author":"Valdivieso M","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_120_2","first-page":"25","article-title":"Initial clinical study with vindesine: tolerance to weekly i.v. bolus and 24\u2010hour infusion","volume":"64","author":"Ohnuma T","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930090310"},{"key":"e_1_2_1_122_2","first-page":"515","article-title":"Phase II study of vindesine sulfate in patients with advanced sarcomas","volume":"65","author":"Sordillo PP","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257191"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257186"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-81488-4_13"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950060403"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1983.tb03269.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1983.tb03269.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1983.tb03269.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:38:48Z","timestamp":1761043128000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1983.tb03269.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,9,10]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1983,9,10]]}},"alternative-id":["10.1002\/j.1875-9114.1983.tb03269.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1983.tb03269.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,9,10]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}